ID   Ramos
AC   CVCL_0597
SY   RAMOS; Ramos 1; RA 1; RA.1; Ra #1; Ra No. 1; Ramos(RA1); Ramos-RA1; Ramos (RA 1); Ramos (RA)
DR   BTO; BTO:0003079
DR   CLO; CLO_0008738
DR   CLO; CLO_0008739
DR   EFO; EFO_0002077
DR   MCCL; MCC:0000410
DR   CLDB; cl4096
DR   CLDB; cl4097
DR   CLDB; cl4098
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-1596
DR   BCRC; 60252
DR   BioSample; SAMN01821590
DR   BioSample; SAMN01821657
DR   BioSample; SAMN03472718
DR   CCRID; 3111C0001CCC000047
DR   CCRID; 3111C0001CCC000048
DR   CCRID; 3111C0002000000052
DR   Cell_Model_Passport; SIDM01094
DR   CGH-DB; 9205-4
DR   ChEMBL-Cells; CHEMBL3307664
DR   ChEMBL-Targets; CHEMBL614629
DR   Cosmic; 929817
DR   Cosmic; 931111
DR   Cosmic; 991547
DR   Cosmic; 998719
DR   Cosmic; 1037704
DR   Cosmic; 1226864
DR   Cosmic; 1509204
DR   Cosmic; 1517660
DR   Cosmic; 1762459
DR   Cosmic; 1818347
DR   DSMZ; ACC-603
DR   ECACC; 85030802
DR   ECACC; 91030710
DR   FCS-free; 243-2-490-3-4-12
DR   GEO; GSM987747
DR   GEO; GSM987748
DR   GEO; GSM987749
DR   GEO; GSM99388
DR   GEO; GSM1374843
DR   GEO; GSM1374844
DR   IARC_TP53; 180
DR   JCRB; JCRB9119
DR   KCLB; 21596
DR   LINCS_HMS; 50811
DR   LINCS_LDP; LCL-1097
DR   Lonza; 725
DR   NCBI_Iran; C128
DR   NIH-ARP; 9938-10
DR   PharmacoDB; RAMOS_1283_2019
DR   PRIDE; PXD000447
DR   Wikidata; Q54949198
RX   PubMed=181343;
RX   PubMed=1850347;
RX   PubMed=1915267;
RX   PubMed=2052620;
RX   PubMed=2835030;
RX   PubMed=3026973;
RX   PubMed=3518877;
RX   PubMed=6231253;
RX   PubMed=6286763;
RX   PubMed=7316467;
RX   PubMed=7757991;
RX   PubMed=8316623;
RX   PubMed=8344493;
RX   PubMed=8515068;
RX   PubMed=8896424;
RX   PubMed=9225077;
RX   PubMed=9473234;
RX   PubMed=9973220;
RX   PubMed=10918597;
RX   PubMed=12967475;
RX   PubMed=18211290;
RX   PubMed=20922763;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=31160637;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=Ramos
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-485.html
WW   http://www.cogcell.org/cellreqs-ncipptp.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=47
WW   http://www.cellresource.cn/fdetail.aspx?id=48
WW   http://www.cellresource.cn/fdetail.aspx?id=424
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Characteristics: EBV-negative.
CC   Doubling time: 20.4 +- 1.5 hours (PubMed=9225077); 14 hours (PubMed=20922763); ~48 hours (DSMZ).
CC   HLA typing: A*03:01,03:01; B*44:03,51:01; C*16:01,16:01; DQA1*02:01,02:01; DQB1*02:01,02:01; DRB1*07:01,14:103 (PubMed=25960936).
CC   Sequence variation: MYC-IGH gene fusion (PubMed=10918597).
CC   Sequence variation: Homozygous for TP53 p.Ile254Asp (c.760_761AT>GA) (PubMed=1915267; PubMed=2052620; PubMed=8344493).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Misspelling: Romas; In CCRID 3111C0002000000052.
CC   Derived from sampling site: Ascites.
ST   Source(s): ATCC; CCRID; COG; DSMZ; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13,14
ST   D16S539: 10,13
ST   D18S51: 15
ST   D19S433: 14,15.2
ST   D21S11: 30
ST   D2S1338: 20,23
ST   D3S1358: 14,15
ST   D5S818: 7,12
ST   D6S1043: 13,15
ST   D7S820: 11
ST   D8S1179: 13,16
ST   FGA: 20,24
ST   Penta D: 10,13
ST   Penta E: 8,21
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 28
//
RX   PubMed=181343; DOI=10.1159/000149930;
RA   Klein G., Giovanella B.C., Westman A., Stehlin J.S. Jr., Mumford D.M.;
RT   "An EBV-genome-negative cell line established from an American Burkitt
RT   lymphoma; receptor characteristics. EBV infectibility and permanent
RT   conversion into EBV-positive sublines by in vitro infection.";
RL   Intervirology 5:319-334(1975).
//
RX   PubMed=1850347; DOI=10.1210/endo-128-5-2266;
RA   Baglia L.A., Cruz D., Shaw J.E.;
RT   "An Epstein-Barr virus-negative Burkitt lymphoma cell line (sfRamos)
RT   secretes a prolactin-like protein during continuous growth in
RT   serum-free medium.";
RL   Endocrinology 128:2266-2272(1991).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=2835030; DOI=10.1016/s0385-8146(87)80025-1;
RA   Takimoto T., Sato H., Ogura H., Miyazaki T.;
RT   "Establishment of an Epstein-Barr virus (EBV) genome-positive subline
RT   of Ramos (Ramos/NPC) following infection of Ramos with nasopharyngeal
RT   carcinoma (NPC)-derived EBV.";
RL   Auris Nasus Larynx 14:87-92(1987).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6286763;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
//
RX   PubMed=7757991;
RA   Bae I., Fan S., Bhatia K., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.;
RT   "Relationships between G1 arrest and stability of the p53 and
RT   p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma
RT   cells.";
RL   Cancer Res. 55:2387-2393(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8515068;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562;
RA   Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.;
RT   "VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic
RT   hypermutation, intraclonal heterogeneity, and a role for antigen
RT   selection.";
RL   Blood 88:3562-3568(1996).
//
RX   PubMed=9225077; DOI=10.1016/S0145-2126(97)00126-4;
RA   Okano M.;
RT   "High susceptibility of an Epstein-Barr virus-converted Burkitt's
RT   lymphoma cell line to cytotoxic drugs.";
RL   Leuk. Res. 21:469-471(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G.,
RA   Magrath I.T., Bhatia K.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=10918597; DOI=10.1038/sj.onc.1203686;
RA   Bemark M., Neuberger M.S.;
RT   "The c-MYC allele that is translocated into the IgH locus undergoes
RT   constitutive hypermutation in a Burkitt's lymphoma line.";
RL   Oncogene 19:3404-3410(2000).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=18211290; DOI=10.1111/j.1365-2184.2007.00500.x;
RA   Zander L., Bemark M.;
RT   "Identification of genes deregulated during serum-free medium
RT   adaptation of a Burkitt's lymphoma cell line.";
RL   Cell Prolif. 41:136-155(2008).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M.,
RA   Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J.,
RA   Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Maria Murga Penas E., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//